Ask a Patient Opinion Poll
As a condition of approval, should the FDA require that a new drug show how it performs compared with existing drugs approved for the same condition?
(Total Votes: 170)
Not sure (4.1%) | |
|
Yes (90.0%) | |
|
No (5.9%) | |
|
Voter Comments (the following are opinions of readers and not AskaPatient.com)
• people hope for miracles and then these drugs turn out harmful
• The patient should have the opportunit to choose. The Patient should have control.
• We spend too much money on similar drugs. A compaison would be very helpful.
• In addition, the "new" drug should have fewer side effects and be significantly better than the prio
• Certainly!
• All the truth, not just profit driven info.
• This could result in fewer and more costly approvals.
• Absolutely it should at the least be more effective and safer
• Medicine should be safe, not cause more harm.
• Without an accurate and valid comparison -- the public has no measurment as to any benefit of a new
• ALL side effects should also be evaluated before experimenting on the patient/public
• Testing only against placebo makes new drugs look goood even thought they may be worse than an old g
• Because there is no such thing as one size fits all with medications
• It should be tested against placebo and against alternatives, expecially GENERIC alternatives.
• Every new drug should be compared to the existing ligitimate comparables! Thats a given!
• New drug regulations are far too arbitrary already. I'd prefer a more stringent review overall.
• For example the old prozac arguably beats new versions.
• WE all TRUST the FDA -- they need to provide absolutely accurate info. to the public -- not specualt
• Should be compared against natural supplements.
• always!
Related Articles
• Study finds including unpublished FDA data alters drug effectiveness outcomes
• Comparative effectiveness approaches not always the most effective
• Many New Drugs Did Not Have Comparative Effectiveness Information Available At Time Of FDA Approval
• New drugs should be compared with existing treatments before approval, say experts